Novartis ($NVS) has put its animal-health unit ahead of the consumer healthcare business on the list of divisions it wants to sell, Bloomberg reports. The consumer drug division has been dogged by quality failings at its troubled plant in Lincoln, NE, but its sale--and that of the vaccines business--is reportedly viewed as a lower priority than offloading the animal-health unit. Article